MedTrace Logo

A Study of FOY-305 in Patients With SARS-Cov-2 Infection (COVID-19)

NCT04657497 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 155

Last updated 2024-04-05

No results posted yet for this study

Summary

To assess the efficacy and safety of FOY-305 in patients with SARS-CoV-2 infection (COVID-19) in a placebo-controlled, multicenter, double-blind, randomized, parallel-group comparative study.

Conditions

  • SARS-CoV-2 Infection (COVID-19)

Interventions

DRUG

FOY-305

Specified Dosage and Duration of Treatment

DRUG

Placebo

Specified Dosage and Duration of Treatment

Sponsors & Collaborators

  • Ono Pharmaceutical Co. Ltd

    lead INDUSTRY

Principal Investigators

  • Naoyuki Komura · Ono Pharmaceutical Co. Ltd

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-09
Primary Completion
2021-03-26
Completion
2021-04-09

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04657497 on ClinicalTrials.gov